West Pharmaceutical Services' (NYSE:WST) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
West Pharmaceutical Services' (NYSE:WST) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a good company can see its share price rise well over 100%. For instance, the price of West Pharmaceutical Services, Inc. (NYSE:WST) stock is up an impressive 266% over the last five years. On the other hand, the stock price has retraced 4.0% in the last week. But note that the broader market is down 3.7% since last week, and this may have impacted West Pharmaceutical Services' share price.
你在任何一隻股票上最多隻能損失100%的錢(假設你不使用槓桿)。但在較輕鬆的情況下,一家好公司的股價漲幅可以遠遠超過100%。例如,價格,西部醫藥服務公司。(紐約證券交易所股票代碼:WST)的股票在過去五年中上漲了266%,令人印象深刻。另一方面,股價在過去一週回調了4.0%。但請注意,自上週以來,大盤下跌了3.7%,這可能影響了West Pharmtics Services的股價。
Although West Pharmaceutical Services has shed US$1.1b from its market cap this week, let's take a look at its longer term fundamental trends and see if they've driven returns.
儘管西方醫藥服務公司本週市值縮水11億美元,但讓我們來看看它的長期基本面趨勢,看看它們是否推動了回報。
See our latest analysis for West Pharmaceutical Services
查看我們對西方醫藥服務公司的最新分析
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
不可否認,市場有時是有效的,但價格並不總是反映潛在的商業表現。考察市場情緒如何隨時間變化的一種方法是觀察一家公司的股價和每股收益(EPS)之間的相互作用。
Over half a decade, West Pharmaceutical Services managed to grow its earnings per share at 28% a year. So the EPS growth rate is rather close to the annualized share price gain of 30% per year. Therefore one could conclude that sentiment towards the shares hasn't morphed very much. Rather, the share price has approximately tracked EPS growth.
在過去的五年裡,西方醫藥服務公司設法使其每股收益以每年28%的速度增長。因此,每股收益的增長率相當接近股價每年30%的年化漲幅。因此,人們可以得出這樣的結論:投資者對這些股票的情緒沒有太大變化。相反,該公司股價已大致追隨每股收益的增長。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下圖顯示了EPS是如何隨著時間的推移進行跟蹤的(如果您點擊該圖像,您可以看到更多詳細資訊)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231025/0-a5ce79d8239a470d68022bda13c4fdb0-0-005e2566685acb66c5a4e7ad078d4040.png/big)
This free interactive report on West Pharmaceutical Services' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
這免費如果你想進一步調查股票,關於West Pharmtics Services的收益、收入和現金流的互動報告是一個很好的起點。
What About Dividends?
那股息呢?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, West Pharmaceutical Services' TSR for the last 5 years was 271%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
在考察投資回報時,重要的是要考慮到股東總回報(TSR)和股價回報。雖然股價回報只反映股價的變動,但TSR包括股息的價值(假設股息再投資),以及任何折價集資或分拆所帶來的利益。公平地說,TSR為支付股息的股票提供了更完整的圖景。碰巧的是,西方醫藥服務公司最近5年的TSR為271%,超過了前面提到的股價回報。這在很大程度上是其股息支付的結果!
A Different Perspective
不同的視角
It's good to see that West Pharmaceutical Services has rewarded shareholders with a total shareholder return of 57% in the last twelve months. And that does include the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 30% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.
很高興看到,在過去的12個月裡,西部藥業服務公司以57%的總股東回報回報了股東。這確實包括了股息。由於一年期的TSR好於五年期的TSR(後者的年收益率為30%),看起來該股的表現在最近有所改善。鑑於股價勢頭依然強勁,仔細觀察這只股票可能是值得的,以免錯過預期和機會。大多數投資者都會花時間檢查內幕交易的數據。你可以點擊這裡,看看內部人士是在買入還是賣出。
But note: West Pharmaceutical Services may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:西方醫藥服務公司可能不是最值得買入的股票。所以讓我們來看看這個免費過去有盈利增長(以及進一步增長預測)的有趣公司名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.